Epiduo 0.1 % / 2.5 % Norvēģija - norvēģu - Statens legemiddelverk

epiduo 0.1 % / 2.5 %

galderma nordic ab - adapalen / benzoylperoksid - gel - 0.1 % / 2.5 %

Epiduo 0.3 % / 2.5 % Norvēģija - norvēģu - Statens legemiddelverk

epiduo 0.3 % / 2.5 %

galderma nordic ab - adapalen / benzoylperoksid - gel - 0.3 % / 2.5 %

Epiduo 0.1 % / 2.5 % Norvēģija - norvēģu - Statens legemiddelverk

epiduo 0.1 % / 2.5 %

2care4 - adapalen / benzoylperoksid - gel - 0.1 % / 2.5 %

Epiduo 0.1 % / 2.5 % Norvēģija - norvēģu - Statens legemiddelverk

epiduo 0.1 % / 2.5 %

2care4 - adapalen / benzoylperoksid - gel - 0.1 % / 2.5 %

Differin 1 mg/ g Norvēģija - norvēģu - Statens legemiddelverk

differin 1 mg/ g

galderma nordic ab - adapalen - gel - 1 mg/ g

Differin 1 mg/ g Norvēģija - norvēģu - Statens legemiddelverk

differin 1 mg/ g

galderma nordic ab - adapalen - krem - 1 mg/ g

Olysio Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

olysio

janssen-cilag international nv - simeprevir - hepatitt c, kronisk - antivirale midler til systemisk bruk - olysio er angitt i kombinasjon med andre legemidler til behandling av kronisk hepatitt c (chc) hos voksne pasienter. for hepatitt c-virus (hcv) genotypen bestemt aktivitet.

Numient Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

numient

amneal pharma europe ltd - levodopa, carbidopa - parkinsonsykdom - anti-parkinson medisiner - symptomatisk behandling av voksne pasienter med parkinsons sykdom.

Teysuno Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafur, gimeracil, oteracil - mage-neoplasmer - antineoplastiske midler - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Prograf 0.5 mg Norvēģija - norvēģu - Statens legemiddelverk

prograf 0.5 mg

astellas pharma a/s - takrolimusmonohydrat - kapsel, hard - 0.5 mg